Latanoprost Aurovitas (Latanoprost)

Latanoprost increases the uveoscleral outflow of aqueous humor, the fluid that fills the front part of the eye. It binds to prostaglandin F‑type receptors in the ciliary muscle, remodeling extracellular matrix and enhancing fluid drainage. This mechanism reduces intra‑ocular pressure, addressing the primary pathogenic factor in glaucoma and ocular hypertension.

The dosing regimen for Latanoprost Aurovitas is determined by the prescribing ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose, frequency, and duration are individualized based on the patient’s intra‑ocular pressure response and clinical condition. Patients should follow the prescriber’s instructions precisely.

Safety data for latanoprost in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternative treatment options with their eye care provider.

To request Latanoprost Aurovitas, visit the product page on gnhindia.com and submit an enquiry specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a quotation. The sales team then confirms pricing, availability, shipping logistics, and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which is generally considered first‑line therapy for glaucoma due to its strong IOP‑lowering effect and once‑daily dosing. Compared with beta‑blocker eye drops, latanoprost often provides greater pressure reduction and has a different side‑effect profile, such as increased eyelash growth. It is not interchangeable with carbonic anhydrase inhibitors or cholinergic agents, which have distinct mechanisms and dosing schedules.

Latanoprost Aurovitas should be stored at room temperature, below 25 °C, in its original container. The bottle must be kept tightly closed, protected from light, and stored away from moisture. Do not freeze the solution. Once opened, the product remains stable for a defined period, typically up to 6 weeks, after which any remaining drops should be discarded.

Latanoprost is administered as a sterile ophthalmic solution. The patient should wash their hands, tilt the head back, and gently pull down the lower eyelid to create a small pocket. One drop is placed into the conjunctival sac of the prescribed eye(s) without touching the tip of the bottle to the eye or surrounding tissues. The eye should be closed gently for a few seconds to aid absorption.

Although uncommon, serious adverse events can occur with Latanoprost. These include severe ocular inflammation such as uveitis or iritis, sudden loss of vision, corneal edema, and allergic reactions that may cause swelling or rash around the eye. Patients experiencing any of these symptoms should seek immediate medical attention. Regular monitoring by an eye care professional helps detect and manage potential complications early.

Latanoprost Aurovitis is contraindicated in individuals with known hypersensitivity to latanoprost or any component of the formulation. It should also be avoided in patients with active ocular infections, severe inflammation, or corneal endothelial dysfunction where the drug may exacerbate the condition. Pregnant or nursing women should only use it if clearly indicated by a healthcare professional after weighing potential risks and benefits.